Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced HER2-Negative Breast Carcinoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT06750848
What this trial is testing

Chidamide Combined With Angiogenesis Inhibitors and Fulvestrant for Advanced HR-positive, HER2-negative Breast Cancer

Who this might be right for
Advanced Breast Cancer
Jundong Wu 48
Testing effectiveness (Phase 2)Looking for participantsNCT06179303
What this trial is testing

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

Who this might be right for
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Locally Advanced Unresectable HER2-Negative Breast Carcinoma+3 more
University of Washington 60
Early research (Phase 1)WithdrawnNCT04498520
What this trial is testing

Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer

Who this might be right for
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8Anatomic Stage IIIB Breast Cancer AJCC v8+32 more
Pamela Munster
Early research (Phase 1)Study completedNCT01276496
What this trial is testing

Weekly Doses of Cilengitide and Paclitaxel in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by Surgery

Who this might be right for
Adult Solid NeoplasmEstrogen Receptor NegativeHER2/Neu Negative+7 more
National Cancer Institute (NCI) 13
Large-scale testing (Phase 3)Study completedNCT01099436
What this trial is testing

Neo-Adjuvant Chemotherapy (TAC) With or Without Zoledronic Acid in Treating HER2-negative Breast Cancer Patients

Who this might be right for
Breast Cancer
Borstkanker Onderzoek Groep 250
Large-scale testing (Phase 3)Looking for participantsNCT06255392
What this trial is testing

Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer

Who this might be right for
Fludzoparib" and Anti-angiogenicHRD-positive/HER2-negative Advanced Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 200
Early research (Phase 1)Looking for participantsNCT04872166
What this trial is testing

BTX-A51 in People With Advanced Solid Tumor and Breast Cancer

Who this might be right for
Advanced Solid TumorMetastatic Breast Cancer
Edgewood Oncology Inc. 112
Testing effectiveness (Phase 2)WithdrawnNCT07570966
What this trial is testing

Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Who this might be right for
Advanced HR+/HER2- Breast CancerAdvanced CCNE1-amplified Solid TumorsMetastatic Castration-resistant Prostate Cancer (mCRPC)
Novartis Pharmaceuticals
Early research (Phase 1)Ended earlyNCT04042480
What this trial is testing

SGN-CD228A in Advanced Solid Tumors

Who this might be right for
Cutaneous MelanomaPleural MesotheliomaHER2 Negative Breast Neoplasms+3 more
Seagen Inc. 88
Early research (Phase 1)Active Not RecruitingNCT04556773
What this trial is testing

A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
AstraZeneca 138
Early research (Phase 1)Looking for participantsNCT06503783
What this trial is testing

BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Negative Breast Cancer and Other Solid Tumors

Who this might be right for
Breast CancerSolid Tumor
Sichuan Baili Pharmaceutical Co., Ltd. 20
Early research (Phase 1)Study completedNCT02754011
What this trial is testing

Phase I Evaluating the Combination of Ribociclib+Capecitabine in Locally Advanced/Metastatic Breast Cancer HER2 Negative

Who this might be right for
Breast Cancer
UNICANCER 18
Early research (Phase 1)Looking for participantsNCT04997993
What this trial is testing

Leflunomide in Patients With PTEN-Altered Advanced Solid Malignancies and HER2 Negative Breast Cancer

Who this might be right for
PTEN-Altered Advanced Solid Tumors and HER2 Negative Breast Cancer
Deborah Doroshow 23
Early research (Phase 1)Looking for participantsNCT07604571
What this trial is testing

Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer

Who this might be right for
Advanced HR+/HER2- Breast Cancer
Novartis Pharmaceuticals 194
Testing effectiveness (Phase 2)Looking for participantsNCT07602907
What this trial is testing

Metronomic Oral Paclitaxel Monotherapy for Advanced HER2-Negative Breast Cancer: A Two-Stage Dose-Finding and Expansion Study

Who this might be right for
Advanced Breast CancerHER2-negative Breast Cancer
Zhejiang Cancer Hospital 73
Testing effectiveness (Phase 2)UnknownNCT06470672
What this trial is testing

Study of SHR-A1921 Combined Adebrelimab in HR-positive, HER2-negative Advanced Breast Cancer

Who this might be right for
Advanced Breast CancerHormone-receptor-positive Breast CancerHuman Epidermal Growth Factor 2 Negative Carcinoma of Breast
Fudan University 32
Testing effectiveness (Phase 2)Study completedNCT06533722
What this trial is testing

Adaptive Therapy for Post-Second-Line Advanced Breast Cancer

Who this might be right for
HER2-negative Metastatic Breast Cancer
Sun Yat-sen University 10
Large-scale testing (Phase 3)Active Not RecruitingNCT05365178
What this trial is testing

To Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer

Who this might be right for
HR-positive, HER2-negative Breast Neoplasms
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 432
Testing effectiveness (Phase 2)Ended earlyNCT04172597
What this trial is testing

Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced Malignancies

Who this might be right for
Breast CancerColorectal CancerSolid Tumor+1 more
Spectrum Pharmaceuticals, Inc 1
Testing effectiveness (Phase 2)UnknownNCT05775575
What this trial is testing

A Clinical Trial of TQB3909 Tablets in Patients With Breast Cancer

Who this might be right for
Advanced Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 65
Next Page